Download
s00066-020-01599-8.pdf 338,35KB
WeightNameValue
1000 Titel
  • Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review
1000 Titelzusatz
  • Risikostratifizierung der Lungentoxizität einer Kombination von Bestrahlung der gesamten Lunge und Hochdosischemotherapie bei Patienten mit Ewing-Sarkom und Lungenmetastasen – eine Übersicht
1000 Autor/in
  1. Scobioala, Sergiu |
  2. Eich, Hans Theodor |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-03-12
1000 Erschienen in
1000 Quellenangabe
  • 196(6):495-504
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00066-020-01599-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248038/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Whole lung irradiation (WLI) represents an important part of multimodal therapy in Ewing sarcoma (EwS) patients diagnosed with pulmonary metastases. This review discusses pulmonary toxicity in EwS patients with pulmonary metastases treated with WLI, who received different modes of high-dose chemotheray (HD-Cth).!##!Methods!#!Literature was compiled using the Cochrane Library, PubMed database, and the National Institute of Health (NIH) clinical trials register. Relevant patient information, including nature of HD-Cth, acute and late lung toxicities, and pulmonary function disorders, was selected from the above databases.!##!Results!#!Nine reports with a total of 227 patients, including 57 patients from a single randomized trial were included in this review. No acute or chronic symptomatic pulmonary toxicities were observed in patients that received WLI after HD busulfan-melphalan (HD-Bu/Mel), but 8% of these patients were diagnosed with asymptomatic restrictive lung disease. Grade 1 or 2 acute or chronic lung adverse effects were observed in up to 30% of patients that received WLI after HD treosulfan/Mel (HD-Treo/Mel) or HD etoposide (E)/Mel. Interstitial pneumonitis was present in 9% of patients treated concurrently with E/Mel and total body irradiation (TBI) with 8 Gy. Radiation doses as well as time between HD-Cth and WLI were both identified as significant risk factors for pulmonary function disorders.!##!Conclusion!#!The risk of adverse lung effects after WLI depends on several factors, including cumulative radiation dose and dose per fraction, HD-Cth regimen, and time interval between HD-Cth and WLI. A cumulative radiation dose of up to 15 Gy and a time interval of at least 60 days can potentially lead to a reduced risk of pulmonary toxicities. No evident adverse lung effects were registered in patients that received simultaneous therapy with HD-Cth and TBI. However, pulmonary function testing and lung toxicity reports were lacking for most of these patients.
1000 Sacherschließung
lokal Procedures and Techniques Utilization [MeSH]
lokal Whole-Body Irradiation/adverse effects [MeSH]
lokal Lung metastases
lokal Lung/radiation effects [MeSH]
lokal Respiratory Function Tests/statistics
lokal Melphalan/administration
lokal Ewing sarcoma
lokal Risk [MeSH]
lokal Busulfan/analogs
lokal Etoposide/administration
lokal Lung side effects
lokal Male [MeSH]
lokal Dose Fractionation, Radiation [MeSH]
lokal Busulfan/adverse effects [MeSH]
lokal Combined Modality Therapy [MeSH]
lokal Child [MeSH]
lokal Radiation Pneumonitis/etiology [MeSH]
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Dose-Response Relationship, Radiation [MeSH]
lokal Lung Neoplasms/radiotherapy [MeSH]
lokal Humans [MeSH]
lokal Melphalan/adverse effects [MeSH]
lokal Review Article
lokal Drug Administration Schedule [MeSH]
lokal Radiotherapy, Intensity-Modulated/adverse effects [MeSH]
lokal Lung Diseases, Interstitial/etiology [MeSH]
lokal Lung Neoplasms/surgery [MeSH]
lokal Lung Diseases, Interstitial/chemically induced [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Busulfan/administration
lokal Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH]
lokal Sarcoma, Ewing/pathology [MeSH]
lokal Young Adult [MeSH]
lokal Chemotherapy
lokal Radiotherapy Dosage [MeSH]
lokal Etoposide/adverse effects [MeSH]
lokal Lung Neoplasms/drug therapy [MeSH]
lokal Lung Neoplasms/secondary [MeSH]
lokal Radiotherapy
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/U2NvYmlvYWxhLCBTZXJnaXU=|https://frl.publisso.de/adhoc/uri/RWljaCwgSGFucyBUaGVvZG9y
1000 Hinweis
  • DeepGreen-ID: f788ff6396a84469a48ade872d5405bc ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6441854.rdf
1000 Erstellt am 2023-04-26T09:52:19.163+0200
1000 Erstellt von 322
1000 beschreibt frl:6441854
1000 Zuletzt bearbeitet 2023-10-19T11:17:33.341+0200
1000 Objekt bearb. Thu Oct 19 11:17:33 CEST 2023
1000 Vgl. frl:6441854
1000 Oai Id
  1. oai:frl.publisso.de:frl:6441854 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source